PRISM: Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) (clinicaltrials.gov) - Apr 14, 2026 - P1/2 | N=21 | Not yet recruiting | Sponsor: Zhongmou Therapeutics | Initiation date: Feb 2026 ➔ Jun 2026
Trial initiation date • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
|